1yr
.png)
1yr
Did you know? The use of mRNA vaccines, originally developed for COVID-19, has opened new avenues in women's health. Researchers are exploring mRNA technology to develop vaccines for conditions like HPV and even breast cancer, potentially leading to new preventive measures and treatments for women’s health issues.
Can mRNA vaccine technology lead to breakthroughs in preventing or treating women's cancers and other reproductive health conditions?
Can mRNA vaccine technology lead to breakthroughs in preventing or treating women's cancers and other reproductive health conditions?
1yr
.png)
1yr
The potential role of CD8+ cytotoxic T lymphocytes and one branch connected with tissue-resident memory in non-luminal breast cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39006029/
Advances in understanding the pathological mechanisms of breast cancer have resulted in the emergence of novel therapeutic strategies. However, triple-negative breast cancer (TNBC), a molecular subtype of breast cancer with...
Advances in TNBC treatment highlight CD8+ TRM cells' crucial role in tumor immunity, offering new insights into immunotherapy and targeting strategies for non-luminal breast cancer.
1yr
Opportunities and Challenges in the Development of Antibody-Drug Conjugate for Triple-Negative Breast Cancer: The Diverse Choices and Changing Needs - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38993251/
Triple-negative breast cancer (TNBC) is a highly heterogeneous breast cancer subtype, which is also characterized by the aggressive phenotype, high recurrence rate, and poor prognosis. Antibody-drug conjugate (ADC) is a...
This review highlights the advancements in antibody-drug conjugates (ADCs) for treating triple-negative breast cancer (TNBC), focusing on sacituzumab govitecan's FDA approval, clinical trials, and future research.